natgillin/translations-raw huggingface dataset:
A history of febrile convulsions, a family history of convulsions, a family history of SIDS (Sudden Infant Death Syndrome) and a family history of an adverse reaction following Tritanrix HepB vaccination do not constitute contra-indications.
Febrilne konvulzije v anamnezi ter konvulzije, SIDS (sindrom nenadne smrti dojenčka) in neželena reakcija po cepljenju s Tritanrix HepB v družinski anamnezi ne predstavljajo kontraindikacije.
Tritanrix HepB is contraindicated if the child has experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis containing vaccine.
Tritanrix HepB je kontraindiciran, če se je pri otroku v 7 dneh po predhodnem cepljenju s cepivom, ki je vsebovalo tudi komponento proti oslovskemu kašlju, pojavila encefalopatija neznane etiologije.
Booster vaccination:
Obnovitveno cepljenje
BEFORE YOUR CHILD RECEIVES TRITANRIX HepB Tritanrix HepB should not be given:
Vaš otrok cepiva Tritanrix HepB ne sme prejeti:
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Tritanrix HepB - Suspension for injection
IME ZDRAVILA IN POT(I) UPORABE Tritanrix HepB - suspenzija za injiciranje DTPw-HBV cepivo
Tritanrix HepB is available in the following pack sizes:
Cepivo Tritanrix HepB je na voljo v naslednjih pakiranjih:
After the marketing of Tritanrix HepB, the following additional side effects have been reported on a few
Po prihodu cepiva Tritanrix HepB na trg so bili v nekaj primerih opisani naslednji neželeni učinki:
In some clinical studies, Tritanrix HepB was used to reconstitute the lyophilised Hib vaccine (Hiberix); no interference in the immune response to any of the antigens was observed as compared to the responses observed following administration of the vaccines at separate sites.
V nekaterih kliničnih študijah so Tritanrix HepB uporabili za rekonstitucijo liofiliziranega cepiva Hib (Hiberix); v primerjavi z odzivi po dajanju cepiv na različna mesta ni bil opažen medsebojni vpliv v imunskem odzivu na katerega od antigenov
HOW TO STORE TRITANRIX HepB
SHRANJEVANJE CEPIVA TRITANRIX HepB
Take special care with Tritanrix HepB:
Bodite posebno pozorni pri cepljenju s cepivom Tritanrix HepB:
The virus is found in body fluids such as blood, semen, vaginal secretions, or saliva (spit) of
Pri okuženih ljudeh se virus nahaja v telesnih tekočinah, kot so kri, sperma, nožnični izločki ali slina
5 ml of suspension in a vial (type I glass) for 10 doses with a plunger stopper (rubber butyl) - pack size of
5 ml suspenzije v viali (steklo tipa I) za 10 odmerkov s potopnim zamaškom (butilna guma) - velikost
What Tritanrix HepB looks like and contents of the pack
Izgled cepiva Tritanrix HepB in vsebina pakiranja
1 ml of suspension in a vial (type I glass) for 2 doses with a plunger stopper (rubber butyl) - pack size of
1 ml suspenzije v viali (steklo tipa I) za 2 odmerka s potopnim zamaškom (butilna guma) - velikost
POSSIBLE SIDE EFFECTS Like all medicines, Tritanrix HepB can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi cepivo Tritanrix HepB neželene učinke, ki pa se ne pojavijo pri vseh cepljenih osebah.
If additional injections are necessary, the doctor will tell you.
Zdravnik vam bo povedal, če so potrebni še dodatni odmerki.
Make sure your child finishes the complete vaccination course of three injections.
Prepričajte se, če je vaš otrok prejel vse tri odmerke in je tako popolno cepljen.
General reactions that may occur in temporal association with Tritanrix HepB vaccination are listed below.
V nadaljevanju so navedene splošne reakcije, ki se lahko pojavijo v časovni povezavi s cepljenjem s cepivom Tritanrix HepB.
Method of administration
NAVODILO ZA UPORABO
WHAT TRITANRIX HepB IS AND WHAT IT IS USED FOR Tritanrix HepB is a vaccine used in children to prevent four diseases: diphtheria, tetanus (lockjaw), pertussis (whooping cough) and hepatitis B. The vaccine works by causing the body to produce its own protection
Tritanrix HepB je cepivo, ki se ga uporablja pri otrocih za preprečevanje štirih bolezni: davice, tetanusa (mrtvičnega krča), oslovskega kašlja (pertusisa) in hepatitisa B. Cepivo deluje tako, da telo spodbudi k proizvajanju lastne zaščite (protiteles) proti tem boleznim.
In a prospective comparative study, which compared the administration of the combined DTPw-HBV vaccine with the simultaneous separate administration of DTPw and HBV vaccine, higher incidences of pain, redness, swelling and fever were reported in the group receiving the combined vaccine.
V prospektivni primerjalni študiji so dajanje kombiniranega DTPw-HBV cepiva primerjali s sočasnim dajanjem cepiva DTPw in cepiva HBV na različna mesta.
Tritanrix HepB is a white, slightly milky liquid presented in a glass vial for 2 doses (1 ml) or in a glass vial
Cepivo Tritanrix HepB je na voljo v obliki bele, rahlo mlečne tekočine v stekleni viali, ki vsebuje 2 odmerka (1 ml) ali v stekleni viali, ki vsebuje 10 odmerkov (5 ml).
Tritanrix HepB can be administered simultaneously at separate sites or in any temporal relationship with other paediatric vaccines if this fits conveniently in the immunisation scheme.
V skladu s programom cepljenja se Tritanrix HepB z drugimi cepivi, ki se jih uporablja v pediatriji, lahko daje sočasno na drugo mesto ali pa v kateremkoli časovnem zaporedju glede na druga cepiva.
This is a multidose container.
Cepivo je na voljo v večodmernem vsebniku.
Tritanrix HepB contains diphtheria (D), tetanus (T) toxoids, inactivated pertussis bacteria (Pw) and the purified major surface antigen of the hepatitis B virus (HBV), adsorbed on aluminium salts.
Tritanrix HepB vsebuje davični (D) toksoid, tetanusni (T) toksoid, inaktivirano bakterijo, povzročiteljico oslovskega kašlja (Pw), in prečiščen glavni površinski antigen virusa hepatitisa B (HBV), ki so adsorbirani na aluminijevih soleh.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING MULTIDOSE VIAL
PODATKI NA ZUNANJI OVOJNINI VEČODMERNA VIALA
The administration of Tritanrix HepB should be postponed in subjects suffering from acute severe
Cepljenje s cepivom Tritanrix HepB je treba odložiti pri osebah s hujšimi akutnimi vročinskimi
• if your child has previously had an allergic reaction to any vaccine against diphtheria, tetanus, pertussis (whooping cough) or hepatitis B diseases.
• če je predhodno imel alergijsko reakcijo na katerokoli cepivo proti davici, tetanusu, oslovskemu
Tell your doctor if your child has any known allergies.
Če ima vaš otrok katerokoli znano alergijo, to povejte svojemu zdravniku.
As for any vaccination, the risk-benefit of immunising with Tritanrix HepB or deferring this vaccination should be weighed carefully in an infant or in a child suffering from a new onset or progression of a severe neurological disorder.
Pri dojenčku ali otroku z novonastalo hudo nevrološko boleznijo ali napredovanjem takšne bolezni je treba tveganje in korist cepljenja s cepivom Tritanrix HepB ali odložitve cepljenja natančno pretehtati, tako kot velja za vsa cepiva.
common: gastro-intestinal symptoms such as vomiting and diarrhoea
pogosti: gastrointestinalni simptomi, kot sta bruhanje in driska pogosti: vnetje srednjega ušesa, faringitis
Tritanrix HepB is indicated for active immunisation against diphtheria, tetanus, pertussis and hepatitis B (HBV) in infants from 6 weeks onwards (see section 4.2).
Tritanrix HepB je indiciran za aktivno imunizacijo otrok, starejših od 6 tednov, proti davici, tetanusu, oslovskemu kašlju in hepatitisu B (HBV) (glejte poglavje 4.2).
Read all of this leaflet carefully before your child starts receiving this vaccine.
Preden vaš otrok prične dobivati to cepivo, natančno preberite navodilo!
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS MONODOSE VIAL
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
3 produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology
3 pridobljen s tehnologijo rekombinantne DNA na celični kulturi kvasovk (Saccharomyces cerevisiae)
The disease affects the airways causing severe spells of coughing that may interfere with normal breathing.
• Oslovski kašelj (pertusis): Oslovski kašelj je zelo nalezljiva bolezen, ki prizadene dihalne poti in povzroča močne napade kašlja, ki lahko ovirajo normalno dihanje.
The potential risk of apnoea and the need for respiratory monitoring for 48-72h should be considered when administering the primary immunisation series to very premature infants (born ≤ 28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity.
Pri osnovnem cepljenju veliko prezgodaj rojenih nedonošenčkov (rojenih pred ali v 28. tednu nosečnosti), še posebej tistih z respiratorno nezrelostjo v anamnezi, je treba upoštevati možnost pojava apneje in potrebo po 48- do 72-urnem spremljanju pljučnega delovanja.
Tritanrix HepB should be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects.
Po intramuskularnem dajanju lahko pri osebah s trombocitopenijo ali z motnjami hemostaze pride do krvavitve, zato je takšnim osebam potrebno Tritanrix HepB dajati previdno.
♦ Common (side effects which may occur in less than 1 per 10 but more than 1 per 100 doses of
• prebavni simptomi, kot sta bruhanje in driska ♦ Občasni (neželeni učinki, ki se lahko pojavijo pri manj kot 1 od 100, vendar več kot 1 od
3 Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology
3 Pridobljen s tehnologijo rekombinantne DNA na celični kulturi kvasovk (Saccharomyces
I.M.
KG
Hypersensitivity after previous administration of diphtheria, tetanus, pertussis or hepatitis B vaccines.
Preobčutljivost po predhodnem cepljenju s cepivi proti davici, tetanusu, oslovskemu kašlju ali
The expected immunological response may not be obtained after vaccination of immunosuppressed patients, e.g. patients on immunosuppressive therapy.
Okužba s HIV ni kontraindikacija za cepljenje proti davici, tetanusu, oslovskemu kašlju in HBV. Cepljenje pri bolnikih z oslabljenim imunskim odzivom, npr. pri bolnikih z imunosupresivnim zdravljenjem, lahko ne vzbudi pričakovanega odziva.
Tritanrix HepB suspension for injection, multidose Diphtheria (D), tetanus (T), pertussis (whole cell) (Pw) and hepatitis B (rDNA) (HBV) vaccine (adsorbed)
Tritanrix HepB suspenzija za injiciranje, večodmerna adsorbirano cepivo proti davici (D), tetanusu (T), oslovskemu kašlju - celotna celica (Pw) in hepatitisu B - rekombinantno (HBV)
EXP: MM/YYYY
≥ 4 i.e.
Tritanrix HepB suspension for injection Diphtheria (D), tetanus (T), pertussis (whole cell) (Pw) and hepatitis B (rDNA) (HBV) vaccine (adsorbed)
Tritanrix HepB suspenzija za injiciranje adsorbirano cepivo proti davici (D), tetanusu (T), oslovskemu kašlju - celotna celica (Pw) in hepatitisu B - rekombinantno (HBV)
Collapse or shock-like state (hypotonic-hyporesponsive episode) Respiratory, thoracic and mediastinal disorders:
kolaps ali šoku podobno stanje (hipotonična-hiporesponzivna epizoda) Bolezni dihal, prsnega koša in mediastinalnega prostora: apneja pri veliko prezgodaj rojenih nedonošenčkih (rojenih pred ali v 28. tednu nosečnosti)
0.26 milligrams Al3+
0,26 miligrama Al3+
0.37 milligrams Al3+
0,37 miligrama Al3+
Your child will receive a total of three injections with an interval of at least one month between each one.
KAKO SE CEPIVO TRITANRIX HepB UPORABLJA Vaš otrok bo prejel skupaj tri odmerke z vsaj enomesečnim vmesnim presledkom.
♦ Uncommon (side effects which may occur in less than 1 per 100 but more than 1 per 1,000 doses of
• zaspanost, razdražljivost, neobičajen jok ♦ Pogosti (neželeni učinki, ki se lahko pojavijo pri manj kot 1 od 10, vendar več kot 1 od
0.5 ml of suspension in a vial (type I glass) with a plunger stopper (rubber butyl) - pack size of 1.
0,5 ml suspenzije v viali (steklo tipa I) s potopnim zamaškom (butilna guma) - velikost pakiranja 1. 6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Tritanrix HepB se lahko meša z liofiliziranim Hib cepivom (Hiberix).
A booster dose with Tritanrix HepB will give rise to increased reactogenicity as would be expected for a booster during the second year of life.
Po cepljenju z obnovitvenim odmerkom cepiva Tritanrix HepB je pojav reakcij na cepivo pogostejši.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING MONODOSE VIAL
PODATKI NA ZUNANJI OVOJNINI ENOODMERNA VIALA
∗ Notes: the information given in this document and its annexes reflects only the CHMP opinion dated 26 June 2008.
* Opombe: Informacije, podane v tem dokumentu in Dodatkih odražajo samo mnenje CHMP z dne 23. junija 2005.
London, 23 October 2008 EMEA/542169/2008
28. november 2005 EMEA/CHMP/383097/2005
The final opinion was converted into a decision by the European Commission on 9 September 2008.
Na podlagi mnenja CHMP je Evropska komisija izdala odločbo dne 28. novembra 2005.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, the amended product information in Annex III and the conditions of the marketing authorisation in Annex IV.
Seznam zadevnih imen proizvodov je naveden v Dodatku I. Znanstveni zaključki so podani v Dodatku II, skupaj s spremenjenim Povzetkom glavnih značilnosti zdravila v Dodatku III.
Written explanations were provided by the MAHs on 14 December 2008, 5 May 2008, 12 June 2008 and 20 June 2008.
Imetnik dovoljenja za promet z etorikoksibom je pisna pojasnila predložil do 10. januarja in 10. maja 2005.
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 31(2) REFERRAL Etoricoxib containing medicinal products International non-proprietary name (INN): etoricoxib BACKGROUND INFORMATION *
MNENJE ODBORA ZA ZDRAVILA ZA UPORABO V HUMANI MEDICINI (CHMP) V ZVEZI Z NAPOTITVIJO IZ ČLENA 31
As these concerns were not resolved during the course of the procedure, and since the 90mg dose of etoricoxib was used in both RA and AS, a notification of an official referral for arbitration under Article 31(2) of Directive 2001/83, as amended to the CHMP was made by France on 19 September 2007.
CHMP je zato na zahtevo ES dne 20. aprila 2005 postopek iz člena 31 Direktive 2001/83/ES, kot je bila spremenjena, ter revizijski postopek v skladu s členom 18 Uredbe Sveta (EGS) št. 2309/93, razširil tako, da se v revizijo razreda zdravil v teku poleg vidikov kardiovaskularne varnosti vključi tudi vrednotenje hudih kožnih reakcij.
Etoricoxib is a selective inhibitor of COX-2 (cyclooxygenase 2) indicated in the symptomatic relief of osteoarthritis (OA, 30-60mg once daily (od)), rheumatoid arthritis (RA, 90mg od) and the pain and signs of inflammation associated with acute gouty arthritis (120mg od).
Zaviralci COX-2, celekoksib, etorikoksib, lumirakoksib, parekoksib, rofekoksib in valdekoksib sestavljajo relativno novo skupino snovi, katerih skupno farmakološko delovanje je selektivno zaviranje ciklooksigenaze-2.
The CHMP concluded that the data confirmed the known renovascular safety profile of etoricoxib (hypertension, oedema and congestive heart failure).
Septembra 2004 je imetnik dovoljenja za promet z rofekoksibom obvestil EMEA, da so podatki iz novega kliničnega preizkušanja (APPROVe) učinkovine rofekoksib pokazali tveganje za trombotične kardiovaskularne dogodke.
The referral procedure was initiated on 20 September 2007 with the adoption of a CHMP list of questions that were to be addressed by the marketing authorisation holders (MAHs).
Zaradi teh podatkov je imetnik dovoljenja za promet dne 30. septembra 2004 z vseh svetovnih tržišč umaknil rofekoksib (Vioxx), pojavila pa so se tudi vprašanja o kardiovaskularni varnosti drugih zaviralcev Cox-2.
On 26 June 2008, the CHMP, having considered the data provided by the MAHs, recommended the granting of the variation to the marketing authorisations.
Po upoštevanju vseh razpoložljivih podatkov je CHMP dne 23. junija 2005 sprejel mnenje za etorikoksib, v katerem priporoča ohranitev dovoljenj za promet za zdravila, ki vsebujejo etorikoksib, za indikacije, navedene v Povzetku glavnih značilnosti zdravila, kot je opredeljeno v Dodatku III.
This referral procedure relates to a request for arbitration concerning the benefit/risk of the 90mg dose of etoricoxib in the treatment of RA and ankylosing spondylitis (AS).
Zaviralci COX-2 so bili v zdravniško prakso uvedeni za zdravljenje bolnikov s kroničnimi vnetnimi boleznimi kot so revmatoidni artritis in osteoartritis.
Based on the review of the available data, the CHMP considered that the benefits of etoricoxib outweigh the risks in the treatment of rheumatoid arthritis and ankylosing spondylitis.
Pfizer je soglašal, da zaradi podatkov o hudih kožnih reakcijah po vsem svetu ustavi prodajo in trženje zdravila Bextra do nadaljnje razprave o neugodnem razmerju med tveganji in koristmi.
Further information on Ebymect can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/ebymect.
Nadaljnje informacije o zdravilu Ebymect so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/ebymect.
Ebymect received a marketing authorisation valid throughout the EU on 15 November 2015.
Za zdravilo Ebymect je bilo 15. novembra 2015 izdano dovoljenje za promet, veljavno po vsej Evropski uniji.
What measures are being taken to ensure the safe and effective use of Ebymect?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ebymect?
The European Medicines Agency decided that Ebymect's benefits are greater than its risks and recommended that it can be authorised for use in the EU.
Evropska agencija za zdravila je zaključila, da so koristi zdravila Ebymect večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Other information about Ebymect
Druge informacije o zdravilu Ebymect
Ebymect must not be used in:
Zdravilo Ebymect se ne sme uporabljati pri:
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ebymect have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Ebymect upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
As for all medicines, data on the use of Ebymect are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Ebymect stalno spremljajo.
Side effects reported with Ebymect are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Ebymect, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Ebymect contains two different active substances, which work in different ways:
Zdravilo Ebymect vsebuje dve različni učinkovini, ki delujeta vsaka na svoj način:
What benefits of Ebymect have been shown in studies?
Kakšne koristi zdravila Ebymect so se pokazale v študijah?
This authorisation was based on the authorisation granted to Xigduo in 2014 (‘informed consent').
Izdaja tega dovoljenja je temeljila na dovoljenju za promet z zdravilom Xigduo, ki je bilo izdano leta 2014 (uporaba dokumentacije s soglasjem).
An overview of Ebymect and why it is authorised in the EU
Pregled zdravila Ebymect in zakaj je odobreno v EU
For further information about using Ebymect, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Ebymect glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Why is Ebymect authorised in the EU?
Zakaj je bilo zdravilo Ebymect odobreno v EU?
• on its own in patients whose disease is not controlled well enough with metformin alone;
kot samostojno zdravilo pri bolnikih, pri katerih bolezni ni mogoče dovolj dobro uravnati samo z metforminom;
HbA1c is a substance in the blood which gives an indication of how well the blood glucose is controlled.
HbA1c je snov v krvi, ki kaže, kako dobro je glukoza v krvi uravnavana.
What are the risks associated with Ebymect?
Kakšna tveganja so povezana z zdravilom Ebymect?
What is Ebymect and what is it used for?
Kaj je zdravilo Ebymect in za kaj se uporablja?
Ebymect can also be used to replace dapagliflozin and metformin taken as separate tablets.
Zdravilo Ebymect se lahko uporablja tudi za nadomestitev dapagliflozina in metformina v obliki ločenih tablet.
When Ebymect is added to treatment with insulin or a medicine that helps the body to produce insulin, such as a sulphonylurea, the doctor may need to lower the dose of insulin or sulphonylurea to prevent hypoglycaemia (low blood sugar levels).
Kadar se zdravilo Ebymect dodaja zdravljenju z insulinom ali zdravilu, ki telesu pomaga pri proizvodnji insulina, kot je sulfonilsečnina, bo moral zdravnik morda zmanjšati odmerek insulina ali sulfonilsečnine, da bi preprečil hipoglikemijo (nizke ravni sladkorja v krvi).
The most common side effects with Ebymect (which may affect more than 1 in 10 people) are hypoglycaemia (when used together with insulin or a sulphonylurea) and gastrointestinal symptoms (symptoms affecting the stomach and gut).
Najpogostejši neželeni učinki zdravila Ebymect (ki se lahko pojavijo pri več kot 1 bolniku od 10) so hipoglikemija (kadar se uporablja skupaj z insulinom ali sulfonilsečnino) in gastrointestinalni simptomi (simptomi, ki prizadenejo želodec in črevesje).
• in combination with other diabetes medicines when these medicines together with metformin are not controlling the diabetes well enough.
v kombinaciji z drugimi zdravili za zdravljenje sladkorne bolezni, kadar ta zdravila v kombinaciji z metforminom zadostno ne uravnavajo bolezni.
Ebymect is available as tablets containing 5 mg of dapagliflozin with 850 mg of metformin and as 5 mg of dapagliflozin with 1,000 mg of metformin.
Zdravilo Ebymect je na voljo v obliki tablet, ki vsebujejo bodisi 5 mg dapagliflozina in 850 mg metformina ali 5 mg dapagliflozina in 1 000 mg metformina.
Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the amount of glucose (sugar) in the blood or when the body cannot use insulin effectively.
Sladkorna bolezen tipa 2 je bolezen, pri kateri trebušna slinavka ne proizvaja dovolj insulina za vzdrževanje primerne ravni glukoze (sladkorja) v krvi ali pri kateri telo insulina ne more učinkovito izrabiti.
• metformin works mainly by reducing glucose production and reducing its absorption from the gut.
metformin deluje predvsem tako, da zavira tvorbo glukoze in zmanjšuje njeno absorpcijo v črevesju.
The recommended dose is 1 tablet taken twice a day with a meal; the strength should be chosen so that in total, patients receive 10 mg of dapagliflozin each day and the same (or almost the same) dose of metformin they were taking before starting Ebymect.
Priporočeni odmerek je ena tableta, ki jo je treba vzeti ob obroku dvakrat na dan, pri čemer se jakost odmerka izbere tako, da bolnik prejme skupno 10 mg dapagliflozina na dan in enak (oziroma skoraj enak) odmerek metformina, kot ga je jemal, preden je prešel na jemanje zdravila Ebymect.
Ebymect is a diabetes medicine that is used, together with diet and exercise in adults with type 2 diabetes.
Ebymect je zdravilo za zdravljenje sladkorne bolezni, ki se skupaj z dieto in telesno vadbo uporablja pri odraslih s sladkorno boleznijo tipa 2.
As a result of the action of both active substances, the blood glucose is reduced and this helps to control type 2 diabetes.
Zaradi delovanja obeh učinkovin se raven glukoze v krvi zniža, kar prispeva k uravnavanju sladkorne bolezni tipa 2.
Ebymect is used:
Zdravilo Ebymect se uporablja:
• dapagliflozin blocks the action of a protein in the kidneys called sodium-glucose co-transporter 2 (SGLT2).
dapagliflozin zavira delovanje beljakovine v ledvicah, imenovane natrij-glukozni soprenašalec 2 (SGLT2).
The Agency considered Ebymect to be effective for treating type 2 diabetes; it also leads to weight loss, which is considered beneficial in patients with diabetes.
Menila je, da je zdravilo Ebymect učinkovito pri zdravljenju sladkorne bolezni tipa 2; poleg tega pa povzroči zmanjšanje telesne mase, kar je koristno za bolnike s sladkorno boleznijo.